CrossAssetDataThe Company File
···
RGEN

Repligen Corporation

Repligen Corporation is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Waltham, MA. Its latest filed balance sheet (2025-12-31) shows total assets of $3.0 billion (its filed statements).

Pre-revenue company Biological Products, (No Diagnostic Substances) Waltham, MA filings since 1995 9 of 9 filed
Ask the desk about RGEN → Compare RGEN with PCVX → Price chart on TradingView ↗ Full EDGAR file ↗ Watch RGEN →

Sector peers: PCVXRVMDCRSPEXEL

5.4/10headline grade
vs its business-model standard
6.1/10past 6.4/10present 4.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.4 out of ten, 9 of 9 metrics filed: past 6.1 out of ten, present 6.4 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 1.7 out of ten. 3 warning events since 2017; the latest 2025-03-03. 17th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 7.9 out of ten. +24.3% a year over 10 filed years; profitable in 9 of 10. 79th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.5 out of ten. Share count shrank 0.5% a year. 4% of cash flow returned. Insiders: 25 sales, 0 purchases. 65th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 7.0 out of ten. ROE 2%: 2¢ of profit per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar. 70th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.8 out of ten. top 32% of 102 in its family; net margin 6.6%. 68th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.1 out of ten. top 49% of 108 in its family for leadership; chief executive since 2024. 51st percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.2 out of ten. bottom 32% of 92 in its family for room to expand. 32nd percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.6 out of ten. bottom 46% of 100 in its family for growth drivers. 46th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 4.2 out of ten. bottom 42% of 72 in its family for expectations against reality. 42nd percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-29 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form 4, 2026-10-08. Filings on record since 1995. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Filtration Products 55%, Chromatography Products 21%, Proteins Products 13%, Process Analytics Products 11%, Other Products under 1%, Royalty under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Loeillot, Olivier (Chief Executive Officer); Hunt, Anthony (Chief Executive Officer); Garland, Jason K (CFO); Bylund, James (Chief Operating Officer); Douglass, Brian Robb (CHIEF PRODUCT OFFICER); Hughes, Violetta (CHIEF ACCOUNTING OFFICER); Kuriyel, Ralf (Senior VP, R&D); Barthelemy, Nicolas (director); Dawes, Karen A (director); Eglinton, Manner Carrie (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-08.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.